Welcome to our dedicated page for Tandem Diabetes SEC filings (Ticker: TNDM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Managing diabetes technology investments is demanding; the latest Tandem Diabetes quarterly earnings report 10-Q filing alone holds dozens of pages on pump shipments, cartridge reorder trends, and FDA milestones. Add device-recall risk updates and the task quickly overwhelms investors. Stock Titan’s AI-powered summaries deliver Tandem Diabetes SEC filings explained simply, so you no longer dig through dense regulatory language.
Inside our dashboard, understanding Tandem Diabetes SEC documents with AI becomes routine. Real-time alerts flag Tandem Diabetes Form 4 insider transactions real-time, letting you see Tandem Diabetes executive stock transactions Form 4 minutes after an officer buys or sells shares. Interactive charts connect these moves to revenue swings highlighted in our Tandem Diabetes earnings report filing analysis.
- AI-powered one-page digests for every report, including the Tandem Diabetes annual report 10-K simplified
- Instant notifications the moment EDGAR releases Tandem Diabetes 8-K material events explained
- Downloadable tables of Tandem Diabetes insider trading Form 4 transactions for custom modelling
Need a concise view of governance or product-pipeline risk? Compare the Tandem Diabetes proxy statement executive compensation tables with pipeline spending trends, cross-linked to segment data in each 10-Q. Whether you monitor patent litigation, track pump adoption rates, or prepare for an upcoming conference call, our comprehensive coverage keeps every filing type in one place and in language you can act on quickly.
Tandem Diabetes Care (NASDAQ:TNDM) filed a routine Form 4 reporting Chief Technology Officer Rick Carpenter’s latest equity transaction.
On June 16 2025, Carpenter acquired 406 common shares through the vesting of previously granted restricted stock units (RSUs) at a stated price of $0. To cover statutory tax withholding, 207 shares were automatically withheld by the company and disposed of at $20.76 per share. Following the transactions, Carpenter directly owns 21,219 shares of Tandem Diabetes Care common stock.
The filing indicates these transfers were executed under the company’s 2013 Stock Incentive Plan and do not involve open-market purchases or sales. No additional derivative positions were reported beyond the RSU conversion.
On 24 June 2025, Southside Bancshares Inc. (SBSI) filed a Form 4 reporting a minor insider transaction by Chief Banking Officer Sherri Anthony. On 20 June 2025, Anthony disposed of 121 common shares at an average price of $27.97 under transaction code F, which typically denotes shares withheld to cover taxes or exercise costs. After the sale, she directly owns 2,937 shares and indirectly holds 550 shares through the company ESOP. No derivative securities or additional transactions were disclosed.
The divestiture represents a very small fraction of both the executive’s total holdings and SBSI’s overall share count, suggesting minimal financial or market impact.
SEC Form 4 filed on 06/18/2025 reveals that Tandem Diabetes Care, Inc. (TNDM) director Myoungil Cha acquired 1,749 shares of common stock on 06/16/2025 through the vesting and settlement of previously granted restricted stock units (RSUs) under the company’s 2013 Stock Incentive Plan. The conversion, reported with transaction code “M,” was executed at $0 cost to the insider and involved no open-market purchase or sale.
Following the transaction, Cha’s direct beneficial ownership rose from 11,950 to 13,699 shares. The RSU grant was originally awarded on 06/15/2022 and vests in three equal annual installments; the reported shares represent the second installment, with additional tranches scheduled for future anniversaries, subject to plan terms.
Key takeaways:
- Insider ownership increase: +1,749 shares, signalling continued alignment with shareholder interests.
- Routine equity compensation: Transaction stems from standard RSU vesting, not discretionary market activity.
- No cash proceeds or sales: Neutral impact on near-term share flow and insider liquidity.
Form 4 filing: On 18-Jun-2025 Tandem Diabetes Care (TNDM) reported that director Joao Paulo Falcao Malagueira acquired 1,749 common shares on 16-Jun-2025 through the automatic settlement of previously granted restricted stock units (RSUs). The RSUs were awarded on 15-Jun-2022 under the company’s 2013 Stock Incentive Plan and vest in three equal annual instalments. No cash consideration was paid (exercise price $0).
Following the conversion, the director’s direct ownership increases to 13,699 TNDM shares. The transaction is coded “M,” indicating a routine equity award vesting rather than an open-market trade, and leaves no remaining derivative securities from this grant. The filing does not signal any strategic or operational changes at the company.
FAQ
What is the current stock price of Tandem Diabetes (TNDM)?
What is the market cap of Tandem Diabetes (TNDM)?
What is the primary focus of Tandem Diabetes?
How do Tandem Diabetes's products stand out in the market?
Which product categories are included in Tandem Diabetes's portfolio?
What markets does Tandem Diabetes serve?
How does the company ensure product safety and quality?
How does Tandem Diabetes generate revenue?
What role does innovation play in Tandem Diabetes's business model?
How does Tandem Diabetes compare with its competitors?
